Olema Pharmaceuticals, Inc. (OLMA)
After hours:
| Previous close | 9.62 |
| Open | 9.60 |
| Bid | 9.66 x 100 |
| Ask | 9.72 x 200 |
| Day's range | 9.35 - 9.96 |
| 52-week range | 5.64 - 17.79 |
| Volume | |
| Avg. volume | 846,393 |
| Market cap | 541.999M |
| Beta (5Y monthly) | 2.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.00 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.75 |
GlobeNewswireOlema Oncology to Participate in Upcoming Investor Conferences in June
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024, at 2:00 p.m. ET Location: Marriott Marquis in New York, NY
Simply Wall St.Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWI
